Company ProfilePremium

Dis-Chem Pharmacies Limited

Company Profile Analysis

Ticker: DCP.JO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Dis-Chem Pharmacies Limited - Company showcase

Year Founded & Workforce

1978

22,000 Employees

Dis-Chem Pharmacies Limited logo

Dis-Chem Pharmacies Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Dis-Chem Pharmacies Limited Overview

Dis-Chem is South Africa's second-largest retail pharmacy chain by store count and, on its own measure, the largest retail pharmacy group by dispensary market share. It operates a vertically integrated model that combines big-box pharmacy-anchored health, beauty and wellness retail (316 Dis-Chem pharmacies and 42 Dis-Chem Baby City stores at February 2026) with a pharmaceutical wholesale and distribution arm. That arm (CJ Distribution / Dis-Chem Distribution) supplies the group's own stores, more than 1,600 independent pharmacies and 280 The Local Choice franchise pharmacies. FY2026 revenue was R42.8bn. Under its first non-founder CEO, Rui Morais, the group is repositioning from "pharmacy retailer" to "integrated healthcare provider and funder". This rests on in-store nurse clinics, the Health Hub store format, health-funding products (Dis-Chem Health medical insurance via Kaelo, and Dis-Chem Life), the data-led Better Rewards loyalty programme, and an in-house innovation unit, X, bigly labs. The strategy compresses near-term earnings: FY2026 HEPS fell 17.3%. It also differentiates the group from its larger, higher-margin rival, Clicks Group.


What the company does

Dis-Chem runs two reportable operating segments, as defined in its FY2025 audited annual financial statements (note 6):

  1. Retail. Dis-Chem pharmacy stores retail pharmaceuticals and a wide range of health and beauty products. The segment also includes pharma-logistic services (Pharma-Logistical Solutions), oncology pharmacy (Dis-Chem Oncology, 50% owned but consolidated through board control), and the specialist baby retail business (Dis-Chem Baby City and the former Baby Boom stores). Since FY2026, Dis-Chem Health (medical insurance and gap cover distribution) has also been reported within core retail.

  2. Wholesale. CJ Wholesale / CJ Pharmaceutical Enterprises and Dis-Chem Distribution wholesale pharmaceutical, health and beauty products. Customers are: (a) the group's own retail stores, which provide most wholesale revenue and are eliminated on consolidation; (b) independent pharmacies (more than 1,600, per the FY2026 integrated report as reported by Business Report); and (c) franchisees of The Local Choice (TLC) pharmacy brand (280 franchise stores at February 2026).

Company's own description

The FY2025 AFS describe Retail as "the Dis-Chem stores, retailers of pharmaceutical and a variety of health and beauty products, as well as pharma-logistic services and oncology", and Wholesale as "the CJ Wholesale and Dis-Chem Distribution businesses, wholesalers of pharmaceutical and a variety of health and beauty products". The FY2026 results (29 May 2026) recast the corporate purpose. The aim is to position the group as "South Africa's healthcare authority", playing a "dual role of healthcare provider and funder", with healthcare delivery creating "a defensive moat that secures the traditional retail basket". The FY2026 integrated report (July 2026) describes an integrated operating model combining retail, wholesale, digital and healthcare services.

Revenue model

Revenue / income streamNatureEvidence
Product sales (retail)Transactional sales of dispensary (regulated Single Exit Price plus dispensing fee), front-shop health, beauty, nutrition and baby productsFY2025 retail category mix: dispensary 36%, personal care & beauty 28%, healthcare & nutrition 22%, baby 8%, other 6% (FY2025 AFS note 7)
Product sales (wholesale, external)Pharmaceutical distribution to independents and TLC franchisees on 30–60-day credit termsExternal wholesale revenue R5.60bn in FY2025 (AFS note 6)
Supplier-funded "other income"Advertising and marketing income, data and administration fees, commissions, franchise feesFY2025 group other income R3.35bn: advertising & marketing R1.24bn; data & admin fees R1.73bn; commission R69m; franchise income R59m; IFRS 16 property-release gain R104m (AFS note 8)
ServicesClinic services (nurse-led consultations, vaccinations, state-contracted family planning and baby vaccinations), virtual GP access, pharma logisticsDisclosed qualitatively; revenue n/d
Insurance / fundingDistribution of Dis-Chem Health medical insurance and gap cover (via the Kaelo associate) and Dis-Chem Life (50% JV, equity-accounted)Kaelo FY2025 revenue R1.18bn (100% basis), group share of profit R13.5m; Dis-Chem Life share of loss R50.2m in FY2026
Loyalty / retail mediaBetter Rewards, a supplier-funded instant-discount programme with 140+ participating brands and Capitec co-fundingR410m returned to customers in the first 17 weeks (trading update, 20 February 2026)

The model is overwhelmingly product-based. Subscription and licensing revenue is immaterial or n/d. The economically important nuance is that supplier income (rebates, advertising, data fees) is a large share of total income. Rebate accounting was the sole key audit matter in Forvis Mazars' FY2025 audit report.

Value-chain position

Dis-Chem sits across two links of the South African private pharmaceutical value chain: wholesale distribution and retail dispensing/merchandising. It is now adding primary-care delivery (clinics, Health Hubs) and health funding (insurance distribution and a life-insurance JV). It does not manufacture medicines. Through Origin Brands (held via the 50% Geniob JV) and its private-label ranges it participates in brand ownership.

Customers and end-markets

Retail consumers: Mass-to-middle-income South Africans. About 9 million legacy Benefit Card members were migrated to Better Rewards in October 2025. The company cited around 15 million customers (Business Day, April 2025) and 1.2 million customers living with chronic conditions (Dis-Chem Life launch, March 2025).

Medical-scheme patients and members: Dispensary revenue depends on medical-scheme benefit cycles; January benefit availability materially lifted retail sales in FY2025 (trading update, February 2025).

Independent pharmacies and TLC franchisees: Wholesale customers.

Suppliers / brand owners: Buyers of retail media, data and promotional services.

The State: Contracted family-planning and baby-vaccination services delivered free to patients through Dis-Chem clinics (Business Day, April 2026).

Independent characterisation

Dis-Chem is best understood as a scale-driven, low-margin health retailer (group operating margin 4.3–5.4% over FY2022–FY2026) whose economics rest on three things: big-box store productivity, wholesale procurement scale, and supplier-funded income. Its rival Clicks earns a materially higher trading margin (9.8% in FY2025) from a far larger, smaller-format pharmacy network (780 pharmacies) with deeper private-label penetration. Dis-Chem's strategic answer is not to imitate Clicks. It aims to "own the patient" through health funding, clinics and data-led loyalty. The bet is still early: FY2026 required R445m of ecosystem and non-recurring spend, and management expects X, bigly labs to turn net-positive only in FY2027.

Strategy

Stated strategy (themes from SENS FY2025, FY2026 and the FY2026 integrated report)

Dis-Chem's strategy has two layers.

Eight strategic areas (introduced under Morais in FY2024/FY2025): store footprint and space growth; people (staffing frameworks); working capital; digital (re-platforming, "digital health ownership"); analytics (commercialising health-consumption data); integrated health ecosystem; wholesale share gains; and cost discipline. Interim FY2025 materials explicitly list "Digital: re-platforming and building capability to ensure digital health ownership" and "Leveraging Analytics: … commercialise health consumption data".

The ecosystem thesis (FY2026). The group aims to transition "from pharmacy retailer to integrated healthcare provider". The stated purposes are increasing access to and reducing the cost of care; playing the "dual role of healthcare provider and funder"; and using healthcare delivery as a "defensive moat that secures the traditional retail basket" (SENS FY2026). The CEO acknowledged in the FY2026 integrated report that shareholders who invested for the earnings track record "have seen a year of disappointing reported results" (Business Report, 3 July 2026).

Initiative register (last 24 months)

InitiativeDateDescriptionTargets / metrics disclosed
Staffing framework 1.0FY2024–FY2025Standardised store staffing mixLike-for-like retail employee costs −0.2% in FY2025; +3.5% in FY2026
Staffing framework 2.0FY2026–FY2027Next phase of retail labour modelIn progress (SENS FY2026 outlook)
Space growthFY2025–FY2027Store roll-out137,000 m² three-year target; 39 stores planned FY2026 (31 delivered); 35 planned FY2027
Working-capital unlockFY2026Excess stock reductionR500m target; inventory flat YoY and inventory days 90.5 → 86.4
Dis-Chem LifeLaunched Feb–Mar 2025Life, funeral and Protector cover JV with OneSpark platform; Guardrisk-underwrittenR155.9m for 50%; FY2026 JV loss R100.4m (Dis-Chem share R50.2m)
X, bigly labsLaunched Nov 2025 (established FY2025)Innovation, data and AI hubR330m FY2026 investment (incl. R27m Dis-Chem Life); net positive returns expected FY2027
Better Rewards + Capitec21 Oct 2025Instant-discount loyalty; Capitec +5%R410m returned in 17 weeks; c. 550,000 new shoppers; volume market share +1.1pp across core retail categories in FY2026
Analytically-led promotional engineFY2026Data-informed promotionsCredited with part of the retail total income margin uplift to 31.1%
Health Hub / Store of the Future6–7 May 2026Integrated clinic, pharmacy and cover formatAll new stores from 1 Aug 2026; existing stores revamped over time
App relaunch7 May 2026Clinic booking, digital scriptsE-commerce relaunch still pending at May 2026
Head-office operating model restructureApr 2026 onwardSection 189 for just over 500 roles; c. 200 new roles in underinvested departmentsEarnings call cited 545 affected employees; under 2.4% of workforce
Strategic partnerships with non-competing brandsFY2026 priorityAccess to mass-market South Africa (Capitec is the first major example)—
People: "20,000 purpose-aligned ambassadors"FY2026–FY2027Employee health and rewards programmeStaff receive +10% Better Rewards boost

Management guidance and medium-term targets

FY2027 guidance (SENS FY2026, 29 May 2026): 35 new retail pharmacies; Store of the Future roll-out; X, bigly labs to be net-positive in FY2027; consumer to remain constrained, with fuel-price increases cited.

First 10 weeks of FY2027 (1 March–19 May 2026): group revenue +9.0%; retail +8.8%; external wholesale +10.4%; total income margin 32.0%.

Financial targets: the earlier 30% total income margin target was met in FY2023. No formal medium-term revenue, margin or ROIC targets were located in the sources reviewed.

Dividend policy: 40% of headline earnings.

Products & Services

Retail segment

OfferingDescriptionKey capabilities / specificationsTarget customerLaunch / latest versionPricing model
Dis-Chem Pharmacy (big-box format)Pharmacy-anchored health, beauty and wellness stores; the core format since 1978Dispensary; front shop of beauty, personal care, vitamins and supplements, sports nutrition, baby, health appliances and fitness equipment; in-store clinic. 316 stores at Feb 2026 (incl. 3 in Namibia, 3 in Botswana per FY2025 AFS)Mass to upper-middle income consumers and medical-scheme membersOngoing; 31 stores opened or acquired in FY2026Retail margin; dispensary regulated by Single Exit Price (SEP) plus a regulated dispensing fee
Health Hub / "Store of the Future"New format integrating pharmacy, clinic and health-cover advice around a central HubDigital queue ticketing; multiple script submission channels (app, digital); upgraded clinic with nurse-led consults, virtual GP access, diagnostic pre-assessment room and clinic care assistant; centralised admin; advisors selling medical, gap, funeral and life coverSame base, plus uninsured and under-insured patientsFirst store Melrose Arch, 6–7 May 2026; mandatory for new stores from 1 Aug 2026Format; monetised through retail, clinic and insurance distribution
Dis-Chem ClinicsIn-store primary-care clinicsNurse consultations, vaccinations, chronic screening, HealthCheck (feeds Better Rewards Health Rating); state-contracted family planning and baby vaccinations free to patientsRetail customers, policyholders, public patientsLong-standing; upgraded 2026Fee-for-service; contract income from the State; detailed pricing n/d
Virtual GP / HealthforceNurse-assisted telemedicineVirtual doctor consultations within clinicsUninsured / low-cost primary careHealthforce 87.5% subsidiary (acquisition date n/d)Per-consult fee (n/d)
Dis-Chem Baby CitySpecialist baby retail format (Baby City acquired Jan 2021; Baby Boom Mar 2022)Prams, car seats, nursery, consumables, clothingParents and expectant parents42 stores at Feb 2026 (down from 54 in FY2023 after rationalisation)Retail margin
Dis-Chem OncologySpecialist oncology pharmacyOncology medicine dispensing and servicesOncology patients and funders50% owned, consolidated (control via board appointments)Regulated medicine pricing
Pharma-Logistical SolutionsPharma logistics service business inside RetailLogistics services (detail n/d)Pharma companies / funders—Service fees
Better RewardsCollaborative, brand-funded instant-discount loyalty programme developed by X, bigly labs10% instant discount on 140+ participating brands; +5% with a Capitec card (15% total); ≥20% for Dis-Chem Health / gap / Life policyholders, up to 100% savings (capped at R3,000/month) linked to HealthCheck rating; staff +10% boost; rewards script adherencec. 9m migrated members plus new shoppers (c. 550,000 new shoppers in the first 17 weeks; 1.1m lapsed or new by May 2026)Live 21 Oct 2025, replacing the Benefit CardSupplier-funded discounts; R115m non-recurring cost to retire the points scheme
Dis-Chem app & e-commerceOnline retail, script submission, clinic bookingClinic booking in 30-minute slots; digital scripts; collection in storeOmnichannel customersRevamped app relaunched 7 May 2026; broader e-commerce relaunch still "soon to be relaunched" per FY2026 SENSRetail pricing
Private label / exclusive brandsOwn and controlled brands (including via the Origin Brands / Geniob JV)Range details n/dValue-seeking shoppers—Retail margin
Tony Ferguson weight-lossHealth and lifestyle ranges (25% associate)Weight-management productsWeight-loss consumers25% acquired FY2023Retail

Health funding and insurance

OfferingDescriptionKey capabilitiesTarget customerLaunchPricing model
Dis-Chem Health (medical insurance and gap cover)Affordable primary-care medical insurance and gap cover distributed by Dis-Chem; Kaelo (25% associate) houses the product portfolioPrimary health insurance, gap cover; occupational clinics and the AskNelson wellbeing platform within KaeloUninsured and under-insured employed consumersKaelo stake from Nov 2021; product growth reported FY2025Monthly premiums (n/d); Kaelo FY2025 revenue R1.18bn and profit R54.1m (100% basis)
Dis-Chem LifeLife, funeral and "Protector" cover sold under the Dis-Chem brand; FSP 50594; underwritten by Guardrisk Life Ltd (FSP 76)AI-driven underwriting; premiums linked to HealthCheck outcomes; at least 20% Better Rewards discount for policyholders; free annual clinic HealthCheckRetail customers, including 1.2m with chronic conditionsLaunched Feb–Mar 2025 (CEO Greg Smith)Risk-rated monthly premiums; JV loss R100.4m in FY2026 (100% basis)

Wholesale segment

OfferingDescriptionCapabilitiesTarget customerPricing model
CJ Distribution / Dis-Chem DistributionNational pharmaceutical wholesaleDistribution centres in Midrand and Longmeadow (Gauteng), Cape Town and KwaZulu-Natal; c. 100,000 m² of DC space in Gauteng alone (Daily Investor, Sept 2026); SAP-hosted stock managementOwn stores, >1,600 independent pharmacies, TLC franchiseesWholesale margin plus logistics and data fees; 30–60-day credit
Nelspruit Pharmaceutical WholesalerRegional wholesaler (Evening Star Trading 204)Mpumalanga regional distributionIndependentsWholesale margin
The Local Choice (TLC) franchisePharmacy franchise brand for independent ownersBuying power, brand, systems; 280 stores at Feb 2026Independent pharmacist-ownersFranchise fees (group franchise income R59m in FY2025) plus wholesale supply
The Pharmacy Development Academy (70%)Pharmacy trainingSkills developmentPharmacists and assistants—
Retail media and data (DC Media, CJ Marketing, Brandwacht Marketing)Supplier advertising, data and administration servicesIn-store and digital media; data and admin feesFMCG and pharma suppliersFees (FY2025 data & admin fees R1.73bn; advertising & marketing R1.24bn across segments)

Innovation unit

OfferingDescriptionStatus
X, bigly labsIn-house innovation, data and technology hub (Melrose Arch; executive head Aliyah Allie). Built Better Rewards, the analytically-led promotional engine and the Health Hub formatEstablished FY2025–FY2026; formal launch Nov 2025; R330m front-loaded investment in FY2026 (including R27m Dis-Chem Life marketing and operating costs); net positive returns expected FY2027

Financial Narrative

Income statement: notes and sources

Sources: FY2023 reviewed results (FY2022–FY2023); FY2025 AFS (FY2024–FY2025); FY2026 from SENS FY2026 commentary, S&P Global Market Intelligence (via StockAnalysis) and Daily Investor (29 May 2026). FY2026 total income, other income, net financing costs, share of associates, EBITDA, D&A, profit for the year and headline earnings are derived as noted.

Margin profile (%)

Growth metrics. Revenue CAGR FY2022–FY2026 was 8.9% (derived: 42,826 / 30,407 over four years). Basic HEPS CAGR over the same period was 3.5%. Operating profit CAGR was 4.7%. Revenue has therefore compounded at more than twice the rate of per-share earnings. This gap is the central analytical fact of the five-year record.

Commentary on income-statement trends

FY2022 (inflection out of COVID). Revenue grew 15.7%, helped by COVID-19 vaccination and testing services and by acquisitions (Baby City, Medicare). The total income margin was only 28.9% because mix favoured low-margin dispensary and COVID-related revenue. Operating margin was 5.1%.

FY2023 (margin step-up, earnings peak on the old model). Revenue growth slowed to 7.4% as COVID services fell away (8.4% retail growth excluding COVID effects). The total income margin jumped 220bp to 31.1%, reaching the group's 30% target "eighteen months sooner than initially anticipated" (FY2023 results). Drivers were the normalisation of category mix, better trade terms and higher service income. HEPS rose 17.4% to 116.5c. Cost pressure was already visible: retail expenses excluding depreciation grew 15.8%, IT costs 32%, and diesel for load-shedding generators rose 65% to R91m.

FY2024 (the earnings stall). Revenue grew a strong 11.1% (wholesale +13.3%), but HEPS fell 1.6% to 114.6c. The total income margin slipped to 30.7%. Payroll ran ahead of sales, finance costs rose 26% on the new property loans, and load-shedding costs persisted. The H1 FY2024 HEPS decline of 17.2% (Reuters/Zawya) triggered the "staffing framework 1.0" programme. FY2024 was also the CEO-transition year.

FY2025 (operating leverage restored). Revenue grew 8.0% and operating profit 18.3%. EPS and HEPS each rose 20.0%; excluding the R103.7m Midrand property gain, HEPS rose 12.3%. The SENS explicitly attributes the improvement to staffing framework 1.0: like-for-like retail employee costs fell 0.2% while comparable store sales rose 4.1%. Retail total income margin rose 60bp to 30.3% on higher transactional gross margin and trade terms.

FY2026 (deliberate earnings sacrifice). Revenue growth accelerated to 9.3%, with retail +9.0% (comparable +5.3%, driven by Better Rewards) and wholesale +13.1%. Operating profit fell 11.9% and HEPS 17.3%. Three factors explain the fall: (1) R445m of ecosystem and non-recurring expense; (2) total expenses up 13.0%, with retail expenses up 15.7% including X, bigly labs headcount and depreciation/amortisation of new technology and stores; and (3) a R50.2m share of Dis-Chem Life's loss. Wholesale margin compressed (total income margin c. 7.2% versus 8.2% excluding the property gain in FY2025) on mix and procurement costs. Underlying retail delivered positive operating leverage: like-for-like sales +5.3% versus like-for-like payroll +3.5%, and retail total income margin up 80bp to 31.1%. In the first 10 weeks of FY2027, the group total income margin reached 32.0% (SENS FY2026 outlook).

Balance sheet

Sources: FY2023 results (FY2022–FY2023); FY2025 AFS (FY2024–FY2025); S&P Global Market Intelligence via StockAnalysis (FY2026, cross-checked to filed FY2022–FY2025 balances).

Notes: the FY2026 overdraft / current-loan split is n/d. S&P reports FY2026 short-term debt of R1,949m and a current portion of long-term debt of R235m. FY2026 receivables per S&P (R3,745m) include other receivables and are defined slightly differently from the filed trade and other receivables line.

Balance-sheet commentary. The defining trend is the move from an asset-light, leased estate to owned logistics real estate. Over FY2022–FY2025, Dis-Chem bought its Cape Town and KZN warehouses (R223m), the 63,000 m² Longmeadow DC (R502m) and the Midrand DC/HQ (R520m), largely with dedicated term loans: R455m from Standard Bank at 3-month JIBAR + 1.44% (5-year bullet), R502m and R650m facilities, and in FY2026 a further R500m two-year bullet extendable to three years. Bank debt excluding leases nearly tripled, from R1.3bn (FY2022) to R3.7bn (FY2026). Lease liabilities fell as owned properties replaced leases. Overdraft usage has risen persistently (R1.32bn at FY2025), and the FY2026 increase in net finance costs was attributed to "the additional overdraft facility being used". Equity has compounded from R3.4bn to R5.7bn, so gearing including leases has edged down (debt/equity 1.33× to 1.17×). Net debt/EBITDA including leases has risen to about 2.0×.

Cash flow

Sources: company cash flow statements (FY2022–FY2025). FY2026 operating cash flow, capex and debt flows from S&P via StockAnalysis, with capex cross-checked to SENS FY2026 (R1.1bn total: R730m expansion, R374m maintenance). The OCF row adds back dividends paid to the company's reported "cash flow from operating activities" (which deducts dividends) so it is comparable with standard OCF definitions.

Cash-flow commentary. Cash generation has been volatile and dominated by working capital and property purchases. FY2023 and FY2025 both saw large inventory build-ups. In FY2025 inventory rose R743m and inventory days reached 90.5 because of new stores and the timing of the SEP buy-in, and free cash flow was negative before leases once the Midrand property was bought. FY2026 marks a clear improvement: inventory was held flat (+R3m) despite 31 new stores, inventory days fell to 86.4, and operating cash flow rose 68% to R2.32bn. This matches the "R500 million working capital unlock" priority set in May 2025. Buybacks are limited to treasury shares for employee schemes; there has been no general repurchase programme.

Ratio analysis

All ratios are analyst-computed from the tables above unless stated. ROE uses average attributable equity (FY2021 attributable equity of R2,909m derived from the FY2023 statement of changes in equity). ROIC = operating profit × (1 − 27% statutory rate) ÷ (closing total equity + net debt including leases).

For comparison, S&P Global (via StockAnalysis, 30 August 2026) reports trailing ROE of 18.96%, ROIC of 11.63%, a current ratio of 1.11, debt/equity of 1.17 and interest coverage of 3.34×, consistent with the analyst calculations.

Ratio commentary. Returns have de-rated in two steps: the cost inflation of FY2024 and the ecosystem investment of FY2026. ROE fell from about 27–28% to 18%. That is still respectable for a low-margin retailer but far below Clicks' 49.2% ROE (Clicks FY2025). ROIC has drifted from 15–16% to about 11%, partly by design: owned property and technology intangibles have expanded invested capital ahead of their returns. The working-capital cycle is structurally favourable, because creditor days exceed inventory days and the group carries net working capital of only about 24 days. This is a key funding advantage of the wholesale-retail model.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey products / servicesKey legal entities (per AFS note 4)

Retail

Dis-Chem pharmacy stores; Dis-Chem Baby City / Baby Boom; Dis-Chem Oncology; pharma-logistic services; clinics; Dis-Chem Health (since FY2026 reported within core retail)

Dispensary, personal care & beauty, healthcare & nutrition, baby care, clinic services

Dis-Chem Pharmacies Ltd (most stores); store subsidiaries (e.g. Dis-Chem Ballito Junction 75%, Dis-Chem Krugersdorp 51%, Dis-Chem Thavhani Mall 65%); Pure Pharmacy Holdings; Healthforce (87.5%); Superstrike Investment 56; Fairy Tales Boutiques; Pharma-Logistical Solutions; The Local Choice Pty Ltd; DC Media

Wholesale

CJ Wholesale and Dis-Chem Distribution

Pharmaceutical, health and beauty wholesale; logistics; franchise support

Dis-Chem Distribution; CJ Pharmaceutical Enterprises; Evening Star Trading 204 (Nelspruit Pharmaceutical Wholesaler); CJ Marketing; Bemax International; Brandwacht Marketing; property companies (CT Distribution Centre, KZN Warehouse, Eleadora, Columbia Falls Properties 7)

Intergroup / consolidation

Elimination of wholesale sales to own retail stores

——

Results by Segment and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025FY2026

Retail revenue (ZAR Mn)

27,10828,88331,69333,57036,600

Wholesale revenue incl. intersegment (ZAR Mn)

21,91124,17927,39030,09934,000

Wholesale revenue to external customers (ZAR Mn; FY2026 derived = group less retail)

3,2983,7804,5915,6036,226

Intersegment elimination (ZAR Mn; FY2026 derived)

-18,613-20,399-22,800-24,497-27,774

Group revenue (ZAR Mn)

30,40732,66436,28339,17242,826

Retail revenue growth YoY (%)

—6.59.75.99.0

Wholesale revenue growth YoY (%)

—10.413.39.913.1

Retail share of group revenue (%)

89.288.487.385.785.5

Wholesale external share of group revenue (%)

10.811.612.714.314.5

Retail total income (ZAR Mn; FY2026 derived at +12.2%)

7,6418,6669,40910,15511,394

Wholesale total income (ZAR Mn; FY2026 derived ex prior-year property gain)

1,63920112,2292,5592,455

Retail total income margin (%)

28.230.029.730.331.1

Wholesale total income margin (%)

7.58.38.18.57.2

Retail EBITDA (ZAR Mn)

2,1602,3392,3572,597—

Wholesale EBITDA (ZAR Mn)

229428519663—

Retail operating profit (ZAR Mn)

1,4171,4321,3761,575—

Wholesale operating profit (ZAR Mn)

115310393519—

Retail operating margin (%)

5.25.04.34.7—

Wholesale operating margin (%)

0.51.31.41.7—

Retail profit before tax (ZAR Mn)

1,1221,0881,0381,232—

Wholesale profit before tax (ZAR Mn)

99327337392—

Retail capex (ZAR Mn)

326578456663—

Wholesale capex (ZAR Mn)

52512571739—

Segment Margins & Growth (%) and Operating Metrics (count)

MetricFY2022FY2023FY2024FY2025FY2026

Retail pharmacy stores at year-end (count; FY2022 and FY2024 derived from openings/closures)

253258268285316

Retail baby stores at year-end (count; FY2022 derived)

3454544542

Comparable pharmacy store revenue growth (%)

—3.3—4.15.3

TLC franchise stores at year-end (count)

147171205240280

Dispensary share of retail revenue (%)

36363536—

Personal care & beauty share of retail revenue (%)

26272828—

Healthcare & nutrition share of retail revenue (%)

24222122—

Baby care share of retail revenue (%)

8898—

Other share of retail revenue (%)

6776—

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (ZAR Mn)

30,40732,66436,28339,17242,826

Revenue growth YoY (%)

15.77.411.18.09.3

Cost of sales (ZAR Mn)

23,57625,07628,06730,37233,417

Gross profit (ZAR Mn)

6,8307,5878,2178,8009,409

Other income (ZAR Mn; FY2026 derived)

1,9612,5872,9083,3473,796

Total income (ZAR Mn; FY2026 derived from reported +8.7%)

8,79210,17411,12412,14813,205

Other expenses incl. D&A (ZAR Mn)

7,2528,4309,34510,04411,350

Depreciation & amortisation incl. right-of-use (ZAR Mn; FY2026 per S&P)

8551,0021,0621,1451,260

EBITDA, company definition (ZAR Mn; FY2026 derived = operating profit + D&A)

2,3952,7692,8863,2703,113

Operating profit (ZAR Mn)

1,5391,7441,7792,1041,853

Finance costs, gross (ZAR Mn)

325370466521554

Net financing costs (ZAR Mn; FY2026 derived from reported +3.3%)

313350440491507

Share of profit of associates & JVs (ZAR Mn; FY2026 derived)

123452048

Profit before tax (ZAR Mn)

1,2271,4171,3851,6341,395

Taxation (ZAR Mn)

337389364414359

Profit for the year (ZAR Mn; FY2026 derived, c. R1.04bn per Daily Investor)

8901,0281,0201,2191,036

Profit attributable to equity holders (ZAR Mn)

8531,0009841,180979

Headline earnings (ZAR Mn; FY2026 derived from HEPS × weighted shares)

8531,0019831,179974

Basic EPS (ZAR cents)

99.2116.3114.7137.6114.2

Diluted EPS (ZAR cents)

99.2116.3114.7137.5—

Basic HEPS (ZAR cents)

99.2116.5114.6137.5113.7

Dividend per share, total declared (ZAR cents)

39.746.5745.7454.8345.34

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

22.523.222.622.522.0

Total income margin (%)

28.931.130.731.030.8

EBITDA margin, company definition (%)

7.98.58.08.37.3

Operating margin (%)

5.15.34.95.44.3

Pre-tax margin (%)

4.04.33.84.23.3

Net margin, attributable (%)

2.83.12.73.02.3

Effective tax rate (%)

27.527.526.325.425.7

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (ZAR Mn)

14,07515,51617,50119,25720,738

Property, plant & equipment incl. right-of-use (ZAR Mn)

3,6894,4294,8005,2975,826

Goodwill (ZAR Mn)

791874930926948

Other intangible assets (ZAR Mn)

419397405522792

Goodwill & intangibles combined (ZAR Mn)

1,2101,2701,3351,4481,740

Investments in associates & JVs (ZAR Mn)

183194208356564

Inventories (ZAR Mn)

5,7596,3577,1637,9057,908

Trade & other receivables (ZAR Mn)

2,1602,5832,7323,3133,745

Cash & cash equivalents (ZAR Mn)

706287884585500

Bank overdraft (ZAR Mn)

4254488511,318—

Loans payable, current (ZAR Mn)

399797488575—

Loans payable, non-current (ZAR Mn)

4795011,2821,6791,510

Bank debt incl. overdraft, excl. leases (ZAR Mn)

1,3031,7462,6213,5723,694

Lease liabilities, total (ZAR Mn)

3,2043,2283,0682,6642,943

Total debt incl. leases (ZAR Mn)

4,5074,9745,6896,2366,637

Net debt excl. leases (ZAR Mn)

5971,4591,7372,9873,194

Net debt incl. leases (ZAR Mn)

3,8024,6874,8065,6506,138

Trade & other payables (ZAR Mn)

5,7886,1046,8647,246—

Total equity incl. NCI (ZAR Mn)

3,3863,9324,4755,2295,694

Equity attributable to parent (ZAR Mn)

3,3243,9004,4725,2185,645

Working capital, current assets less current liabilities (ZAR Mn)

1,3401,0981,7401,7671,178

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Cash inflow from trading operations (ZAR Mn)

2,4132,7832,8783,223—

Movement in working capital (ZAR Mn)

45-718-175-924—

Operating cash flow after interest and tax, before dividends (ZAR Mn)

1,8361,3201,8901,3772,317

Capex to maintain operations (ZAR Mn)

140723158942374

Capex to expand operations (ZAR Mn)

237367869461730

Total capex (ZAR Mn)

3771,0901,0271,4021,104

Free cash flow = OCF less capex (ZAR Mn)

1,459230863-251,213

Lease liability repayments (ZAR Mn)

510565587641—

Free cash flow after lease repayments (ZAR Mn)

949-335276-666—

Dividends paid incl. to NCI (ZAR Mn)

459466424472—

Treasury share purchases (ZAR Mn)

12296533—

Acquisitions of businesses & JVs, net of cash (ZAR Mn)

2664455156—

Bank loans raised (ZAR Mn)

5371,3171,2011,372629

Bank loan and lease repayments combined (ZAR Mn)

9421,4911,3291,5251,541

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

Return on average equity (%)

27.427.723.524.418.0

Return on closing assets (%)

6.36.65.86.35.0

ROIC, closing invested capital (%)

15.614.814.014.111.4

Current ratio (x)

1.181.131.191.171.11

Debt to equity incl. leases (x)

1.331.261.271.191.17

Net debt incl. leases to EBITDA (x)

1.591.691.671.731.97

Net debt excl. leases to EBITDA (x)

0.250.530.600.911.03

Interest coverage, operating profit / gross finance costs (x)

4.74.73.84.03.3

Asset turnover, revenue / closing assets (x)

2.162.112.072.032.07

Inventory days (company-reported)

88.688.288.190.586.4

Creditor days (company-reported)

——93.293.992.3

Net working capital days (company-reported)

26.528.121.724.824.4

Operating Metrics (count)

MetricFY2022FY2023FY2024FY2025FY2026

Namibia stores (count)

———3—

Botswana stores (count)

———3—

Total retail stores, pharmacy + baby (count)

287312322330358

TLC franchise stores, South Africa (count)

147171205240280

Share Price and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Closing share price at FY end (ZAR)

34.6227.05———

12-month share price high (ZAR)

38.2038.45———

12-month share price low (ZAR)

21.8127.03———

Basic HEPS (ZAR cents)

99.2116.5114.6137.5113.7

Interim DPS (ZAR cents)

19.528.123.2526.9829.42

Final DPS (ZAR cents)

20.218.4522.4927.8515.92

Total DPS (ZAR cents)

39.746.5745.7454.8345.34

Net asset value per share (ZAR cents)

393.7457.4521609659

Shares in issue incl. treasury (millions)

860.08860.08860.08860.08860.08

Share Price History

PeriodApproximate price changeBasis

1 year

−15.3%

S&P 52-week change to 28 Aug 2026

About 3.5 years

−4.7%

R27.05 (28 Feb 2023) to R25.78 (14 Sep 2026)

About 5 years

−17.5%

R31.25 (11 Jun 2021) to R25.78 (14 Sep 2026)

Valuation Multiples

MultipleDis-Chem at R25.78 (14 Sep 2026, analyst-derived)Dis-Chem at R28.80 (S&P, 28 Aug 2026)Clicks Group

Market cap (ZAR Bn)

22.124.66

88.0 (31 Aug 2025)

Enterprise value incl. leases (ZAR Bn)

28.230.84—

P/E on basic EPS (x)

22.625.24

n/d (current)

Forward P/E (x)

—19.96—

EV/EBITDA (x; company EBITDA incl. IFRS 16)

9.1

10.10 (S&P EBITDA basis)

—

EV/Sales (x)

0.660.72—

P/B (x)

3.94.33—

Dividend yield (%)

1.761.53—

Analyst Conclusions

Management guidance (SENS FY2026, 29 May 2026)

  • Consumer expected to remain constrained, with fuel-price increases a named headwind.

  • 35 new retail pharmacies in FY2027 (8 trading by 19 May 2026); Store of the Future design for all stores with beneficial occupation from 1 August 2026.

  • X, bigly labs expected to generate net positive returns in FY2027.

  • Restructured operating model with about 200 new roles in underinvested functions.

  • Staffing framework 2.0; digital and e-commerce relaunch.

  • Trading for 1 March–19 May 2026: revenue +9.0%; retail +8.8%; external wholesale +10.4%; total income margin 32.0%.

Consensus expectations

Consensus (S&P, August 2026) implies revenue growth of about 9.6% a year and EPS growth of about 21.9% a year over three years. That is effectively a recovery to and beyond FY2025 earnings by FY2027–FY2028. The forward P/E of about 20× at R28.80 implies a forward EPS of about 144c (derived), above the FY2025 peak of 137.6c.

Bull case

  1. The FY2026 earnings dip is investment, not erosion. Adjusted group PBT rose 20.1% and core retail PBT 27.1% excluding R445m of ecosystem and non-recurring spend. R115m of that spend was explicitly non-recurring, and X, bigly labs is guided to be net-positive in FY2027. A normalisation of these costs alone could restore HEPS toward the FY2025 level.

  2. Margin and cash inflection already visible. The total income margin reached 32.0% in early FY2027 (versus 30.8% in FY2026), Better Rewards drove a 1.1pp volume share gain, and operating cash flow rose 68% to R2.32bn on flat inventory. A low-margin retailer with improving gross economics and disciplined working capital can deliver outsized EPS leverage; consensus expects about 22% annual EPS growth.

  3. Valuation is undemanding for a structural grower. At about R25.78, the stock trades on about 22.6× depressed trailing EPS, about 0.66× EV/Sales and about 9× EV/EBITDA. Revenue has compounded at 8.9% and the store base is growing about 10% a year (35 stores on 316). The founder-family overhang is clearing, and the board is now independent-majority.

Bear case

  1. Structural profitability gap persists. Operating margin has never exceeded 5.4% in five years while Clicks earns 9.8%. Wholesale margin fell about 100bp in FY2026. Each new initiative (clinics, insurance, loyalty discounts, technology) adds cost before revenue, and ROIC has declined from about 15.6% to about 11.4%.

  2. The ecosystem bet is unproven and competitively exposed. Dis-Chem Life lost R100.4m in its first full year against entrenched insurers and Capitec Life. Better Rewards depends on continued supplier funding. Management's "net positive in FY2027" is a target, not a track record, and FY2026 already missed the earnings trajectory implied by FY2025.

  3. Balance sheet and shareholder-structure risks. Bank debt excluding leases nearly tripled to R3.7bn, interest cover fell to 3.3×, and the dividend was cut 17%. About 217m shares now sit with non-executive heirs who sold about R642m in early 2026. The share price trend (−15% over 52 weeks, below both moving averages) reflects these concerns.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
H1 FY2027 interim results30 Oct 2026HEPS growth versus H1 FY2026 (73.8c); total income margin (32.0% run-rate?); X, bigly labs cost run-rate; Dis-Chem Life losses
Clicks Group FY2026 resultsc. late Oct 2026Relative pharmacy share and margin trends
Better Rewards anniversaryFrom 21 Oct 2026Like-for-like growth once the launch base effect laps
Health Hub roll-outFY2027Number of new and revamped stores; revenue per m²; clinic utilisation
Section 189 conclusionH2 2026Final headcount reduction; cost savings versus the 200 new hires
Saltzman heir share sales / block tradesOngoingOverhang release; new strategic holders
SEP determinationAnnual (typically Q1 calendar year)Size of the permitted price increase and its effect on dispensary and wholesale margins
Trading updatec. Feb 2027Festive-season and January medical-benefit trading
FY2027 resultsc. late May 2027Delivery of the "net positive" X, bigly labs return; dividend recovery
Debt and covenantsOngoingOverdraft usage; refinancing of the R455m bullet (c. FY2028)

Concluding analyst verdict

Dis-Chem enters FY2027 at the most consequential juncture since its 2016 listing. The founding Saltzman family, whose discount-pharmacy concept built a R42.8bn revenue group from a 75 m² corner shop, has fully exited both management and the board. In its place is a professional executive team led by Rui Morais. It has made an explicit, capital-intensive bet that the group can earn superior long-run returns by becoming an integrated healthcare provider and funder rather than a pure pharmacy retailer.

The evidence is genuinely mixed. On the positive side, the core engine is working. Revenue grew 9.3% in FY2026 with comparable pharmacy sales up 5.3%. Retail total income margin expanded to 31.1%, and the early-FY2027 group margin of 32.0% suggests Better Rewards is accretive rather than margin-dilutive. Working capital discipline produced the strongest operating cash flow in five years. Adjusted for ecosystem investment, earnings grew about 18–20%.

On the negative side, reported earnings fell 17% and the dividend was cut. Leverage has risen materially to fund owned logistics property. Wholesale margins compressed. The insurance JV is loss-making in a market of formidable incumbents. Most importantly, the five-year record shows revenue compounding at nearly 9% while HEPS compounded at only 3.5%. That pattern suggests the company has historically struggled to convert scale into per-share value, and Clicks continues to earn roughly double the margin and ROE.

The share price, down about 15% over 12 months to about R25.78, prices in considerable scepticism. The investment case now turns on a single, testable proposition: whether the FY2026 investment year is followed by visible operating leverage in H1 FY2027 (reporting 30 October 2026). Delivery would validate the strategy and the consensus recovery path. A second year of cost growing ahead of income would reinforce the bear thesis that Dis-Chem's ecosystem ambitions dilute rather than enhance shareholder returns.


APPENDIX: SOURCES

Primary filings (JSE SENS / company)

Market data

News and secondary sources

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundEducationAge

Rui Morais

Chief Executive Officer, executive director

CEO since 1 Jul 2023; joined 2010; previously CFO

Group CFO before succession; led FY2025 operating-leverage recovery and the ecosystem strategy

Chartered Accountant, CA(SA) (FY2023 results)

—

Julia (JD) Pope

Chief Financial Officer, executive director

CFO since 1 Jul 2023; joined 2017 as executive head of finance

19 years of retail experience at appointment (May 2023)

—

42 at May 2023 (c. 45 now)

Aliyah Allie

Executive Head, X, bigly labs

FY2026–

Leads the innovation unit (Better Rewards, Health Hub)

——

Greg Smith

CEO, Dis-Chem Life (50% JV)

2025–

Life-insurance platform founder side (OneSpark)

——

Prescribed officers (FY2025 AFS)

BI Epstein, CJ Williams, CR Fairweather, CA Swanepoel, TJ Ponter, R Govender, Z Dindar, Q Cronje (KS Sterling listed as a comparative)

—

Titles n/d in sources reviewed

——

Board of Directors

NameRoleIndependenceCommittees (where disclosed)Tenure / notes

Larry (LM) Nestadt

Chairman

Independent non-executive (classified independent in FY2023 results)

—

Chairman since at least the 2016 listing; indirect interest of 500,000 shares (FY2025 AFS)

Ahmed Coovadia

Non-executive director

Independent

Audit & Risk

Indirect interest 162,162 shares

Joe (JS) Mthimunye

Non-executive director

Independent

Chairman, Audit & Risk Committee

Indirect interest 81,162 shares

Anushka (A) Sithebe

Non-executive director

Independent

Audit & Risk

—

Hlengiwe Masondo

Non-executive director

Independent

Audit & Risk

Appointed 14 Jul 2022

KKD (Kgomotso) Kobue

Non-executive director

Listed as independent (FY2023)

Audit & Risk (non-voting member)

—

Rui Morais

CEO

Executive

—

Board member since at least FY2023

Julia Pope

CFO

Executive

—

Since 1 Jul 2023

Board of Directors by Director

DirectorChangeEffective dateSource

Saul (SE) Saltzman

Executive director → non-independent NED

27 Feb 2026

SENS FY2026

Saul Saltzman

Resigned as NED

17 Jul 2026

Company statement, 20 Jul 2026

Stanley (SRN) Goetsch

Retired as executive director after 42 years

30 Jun 2026

SENS FY2026; BusinessTech

Ivan (IL) Saltzman

Retired as executive director; became NED (announced as Deputy Chairman)

30 Jun 2026

SENS FY2026; BusinessTech

Ivan Saltzman

Resigned from board

23 Jul 2026

Daily Investor (company statement)

Lynette Saltzman

Stepped down as executive director (operational role in beauty)

14 Jul 2022

FY2023 results

MJ Bowman

Resigned as NED

14 Jul 2022

FY2023 results

Major Shareholders

HolderStakeDate / basisSource

Coronation Asset Management (clients)

29.83%

Feb 2024, after buying 50m shares from Ivlyn

Business Day, 31 Jan 2024; Daily Investor

Ivlyn Local Investment Holdings (Saltzman vehicle)

29.31% before June 2025; c. 4.1% after (derived)

217m shares distributed 20 Jun 2025

Daily Investor

Mark Saltzman (direct)

c. 11–12% (derived)

Received c. half of 217m shares (reported as R3.4bn each); sold c. R321m in Jan–Feb 2026

Daily Investor; BusinessTech

Dan Saltzman (direct)

c. 11–12% (derived)

As above

As above

Public Investment Corporation (PIC)

Just above 10%

Nov 2023

Business Day, 31 Jan 2024

Allan Gray (clients)

5.4574%

11 Sep 2025 (crossed notifiable threshold)

FilingReader (SENS)

Royal Bafokeng Holdings

6.6%

As reported Aug 2024

Cape Times, 5 Aug 2024

Stansha

4.6%

As reported Aug 2024

Cape Times, 5 Aug 2024

SRN Goetsch (indirect)

29.9m shares (c. 3.5%)

FY2025 AFS (down from 39.9m in FY2024)

FY2025 AFS

CJ Williams (prescribed officer, indirect)

11.2m shares (c. 1.3%)

FY2025 AFS

FY2025 AFS

BI Epstein (prescribed officer, indirect)

9.1m shares (c. 1.1%)

FY2025 AFS

FY2025 AFS

Institutional ownership (aggregate)

68.22%

Aug 2026

S&P via StockAnalysis

Insider ownership (aggregate)

4.77%

Aug 2026

S&P via StockAnalysis

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs Dis-ChemScale indicators (where verified)

Retail pharmacy / health & beauty

Clicks Group (Clicks, UniCare, The Body Shop, Sorbet, M-Kem)

Market leader; smaller-format, higher-density estate; higher private-label share

FY2025 (Aug YE) turnover R47.8bn (+5.3%); trading margin 9.8%; 990+ stores; 780 pharmacies; retail pharmacy market share 24.0%; DHEPS 1,361.7c (+14.1%); ROE 49.2%; market cap R88.0bn (Clicks FY2025)

Retail pharmacy (grocery-anchored)

Shoprite Holdings (MediRite)

In-supermarket pharmacies with grocery footfall

144 MediRite pharmacies (BusinessTech, Oct 2025); pharmacy revenue n/d

Retail pharmacy (grocery-anchored)

SPAR Group (Pharmacy at SPAR)

Franchised in-store pharmacies

125 pharmacies (BusinessTech); revenue n/d

Independent pharmacy networks

Alpha Pharm

Buying group / brand for independents; competes with TLC

350+ pharmacies (BusinessTech)

Independent pharmacy networks

Link Pharmacy

Independent pharmacy network

300+ pharmacies (BusinessTech)

Pharmaceutical wholesale

United Pharmaceutical Distributors (UPD, Clicks Group)

Largest competitor to CJ Distribution in full-line wholesale

UPD trading margin 3.3% (Clicks FY2025); turnover growth 5.1%

Health & beauty retail

Woolworths, Foschini/TFG beauty, Edgars, online marketplaces (e.g. Takealot)

Competition in beauty and personal care

—

Baby retail

Clicks (baby), PEP/Ackermans (Pepkor), online marketplaces

Commoditisation of baby consumables

—

Primary-care / clinics

Clicks clinics; GP practices; occupational health providers

Competes with Dis-Chem Clinics and Health Hubs

—

Health funding / insurance

Discovery, Old Mutual, Momentum, Sanlam, OUTsurance, Capitec Life

Competes with Dis-Chem Life and Dis-Chem Health

n/d (large, entrenched insurers)

Peer Comparison FY2026

MetricDis-Chem (FY2026, Feb YE)Clicks Group (FY2025, Aug YE)Shoprite – MediRiteSPAR – Pharmacy at SPAR

Revenue (ZAR Bn)

42.847.8

n/d (pharmacy not reported separately)

—

Revenue growth (%)

9.35.3——

Operating / trading margin (%)

4.3 (5.4 adjusted)

9.8——

Total income margin (%)

30.831.1——

HEPS growth (%)

−17.3

+14.1 (diluted)

——

ROE (%)

c. 18

49.2——

Pharmacies (count)

316780144125

R&D intensity (% of revenue)

n/d (ecosystem spend 1.0%)

———

Dividend payout policy

40% of HEPS

65% payout (FY2025)

——

Company Snapshot

$2,379.2M

Revenue

22,000

Employees

1978

Founded

Midrand, South Africa

Headquarters

SWOT Analysis

Strengths

  • Consistent top-line growth. Revenue CAGR of 8.9% over FY2022–FY2026, from R30.4bn to R42.8bn, with every year at or above 7.4%.
  • Integrated wholesale platform. Wholesale revenue of R34.0bn (FY2026, +13.1%), external customers growing 11.3%, and the TLC network expanded from 147 to 280 franchise stores in four years.
  • Favourable working-capital structure. Creditor days (92.3) exceed inventory days (86.4), giving net working capital of only 24.4 days in FY2026; FY2026 operating cash flow rose 68% to R2.32bn.
  • Retail margin momentum. Retail total income margin rose from 28.2% (FY2022) to 31.1% (FY2026); the group total income margin reached 32.0% in the first 10 weeks of FY2027.
  • Proven labour productivity programme. Staffing framework 1.0 held like-for-like payroll growth at −0.2% (FY2025) and +3.5% (FY2026) against like-for-like sales of +4.1% and +5.3%.
  • Owned logistics real estate. Midrand, Longmeadow (63,000 m²), Cape Town and KZN DCs are owned, reducing landlord risk and supporting capacity for store-count doubling.
  • Loyalty traction. About 550,000 new shoppers in 17 weeks, R410m returned to customers, and volume market share up 1.1pp.

Weaknesses

  • Low and recently compressed profitability. Operating margin of 4.3% in FY2026, versus Clicks' 9.8% trading margin.
  • Earnings volatility. HEPS moved −1.6% (FY2024), +20.0% (FY2025) and −17.3% (FY2026); HEPS CAGR was only 3.5% over FY2022–FY2026.
  • Rising leverage and finance costs. Bank debt excluding leases rose from R1.3bn to R3.7bn (FY2022–FY2026); gross finance costs rose from R325m to R554m; interest cover fell from 4.7× to 3.3×.
  • Wholesale margin dilution. Wholesale total income margin fell from 8.2% (excluding property gain) to about 7.2% in FY2026 on mix and procurement costs.
  • Baby business underperformance. Store count down from 54 to 42 (FY2023–FY2026) and FY2026 category growth of 5.3%.
  • Weak transformation credentials. B-BBEE Level 8 (55.7 points, August 2022), later reported as Level 6 meeting only one of five minimum requirements (Cosatu, August 2024).
  • Dividend cut. Total DPS fell from 54.83c to 45.34c in FY2026; the final dividend fell 42.8%.

Opportunities

  • Health Hub roll-out. All new stores from August 2026 are built to the format, and the existing estate is to be revamped. Management states it lowers cost to serve and raises revenue per m².
  • Health funding monetisation. Kaelo revenue grew from R815m to R1.18bn (FY2024–FY2025, 100% basis); Dis-Chem Health is now contributing positively within retail; Dis-Chem Life can scale on the 9m+ member base.
  • X, bigly labs payback. Management expects net positive returns in FY2027 from a R330m FY2026 investment base.
  • Space growth. 35 new pharmacies planned for FY2027 against a 137,000 m² three-year target; Dis-Chem is described as adding outlets at close to 50 a year (TimesLIVE, May 2026).
  • Independent-pharmacy consolidation. 1,600+ independents served plus the TLC franchise conversion pipeline (TLC +16.4% in FY2026).
  • Retail media and data. Data and administration fees of R1.73bn and advertising income of R1.24bn in FY2025 can expand with Better Rewards data richness.
  • GLP-1 and chronic medication growth, which management credited with driving pharmacy revenue.

Threats

  • Clicks' scale and pace. 780 pharmacies with net 60 opened in FY2025, plus the UniCare and Sorbet acquisitions and private-label strength (R9.7bn of turnover).
  • Persistent consumer pressure and fuel-price increases, cited in the FY2026 outlook and the July 2026 chairman's statement.
  • Regulatory pricing. SEP increases set by the state cap dispensary and wholesale margin growth.
  • NHI implementation uncertainty for private health funding and dispensing channels.
  • Insurance incumbents. Discovery, Old Mutual, Momentum, Sanlam and Capitec Life (launched 2024) compete with the loss-making Dis-Chem Life (FY2026 JV loss R100.4m).
  • Share overhang. Mark and Dan Saltzman received 217m shares between them in June 2025 and sold about R642m combined in early 2026, and the founding family no longer has board representation.
  • Execution and talent risk from the Section 189 restructuring (just over 500 to 545 affected roles), flagged on the earnings call as an IP-retention risk.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
26 May 2025Trading statement: FY2025 EPS/HEPS expected at 136.4–138.8c (+19–21%)Confirms earnings recovery
30 May 2025FY2025 results: revenue +8.0% to R39.2bn; EPS/HEPS +20.0%; total DPS 54.83c (+19.9%); 9 stores already trading in FY2026; 39 plannedPeak of the "operating leverage" phase; shares fell 5.5% on the day to R33.91
30 May 2025FY2026 priorities: Store of the Future, loyalty relaunch, staffing framework 2.0, R500m working-capital unlock, digital revampSets the FY2026 agenda
20 Jun 2025Ivlyn distributes 217m shares (R6.8bn) within the Saltzman familyShift from a founder holding vehicle to individual heirs; raises overhang risk
23 Jun 2025Final FY2025 dividend of 27.85c paid—
11 Sep 2025Allan Gray clients' stake rises to 5.4574%New notifiable institutional holder
1 Oct 2025Staff Better Rewards boost (+10%) effectiveEmployee engagement
10 Oct 2025Better Rewards and Capitec partnership announced; 9m Benefit Card members to migrateLargest loyalty overhaul in 23 years
Oct 2025Saul Saltzman's resignation as executive director announced (effective Feb 2026)Family exit from management
21 Oct 2025Better Rewards goes liveKey revenue driver for H2 FY2026
30 Oct 2025H1 FY2026 results: revenue +8.7% to R21.3bn; EPS 73.9c (+9.6%); HEPS 73.8c; interim DPS 29.42c (+9%); 302 pharmacies and 44 baby stores; revenue +9.7% for the two months to 26 OctCore retail profit +25.8%; positive pre-launch momentum
Nov 2025X, bigly labs formally launchedFormalises the innovation unit
Late 2025Ivan Saltzman to retire as executive director in June 2026 and continue as NED and Deputy ChairmanSuccession step
Jan–Feb 2026Mark and Dan Saltzman sell about R321m of shares each (e.g. at R36.50 in February 2026)Supply overhang
20 Feb 2026Trading update (1 Sep 2025–16 Feb 2026): revenue +10.1%; retail +9.5%; wholesale +15.7%; 355 retail stores; 281 TLC; R410m savings returned; about 550,000 new shoppers; market share +0.8ppValidates Better Rewards traction
27 Feb 2026Saul Saltzman becomes non-independent NEDBoard transition
24 Apr 2026Section 189 process launched for just over 500 head-office staff; about 200 new roles plannedOperating-model reset; reputational and IP-retention risk
6–7 May 2026Melrose Arch Health Hub (323rd outlet) and revamped app launched; 1.1m Better Rewards members had not shopped in the prior 12 months and nearly 500,000 were entirely newStrategic proof point
29 May 2026FY2026 results: revenue +9.3% to R42.8bn; operating profit −11.9%; HEPS −17.3% to 113.7c; final DPS 15.92c (−42.8%); R445m ecosystem spend; adjusted PBT +20.1%Reported earnings reset
29 May 2026Retirement of Ivan Saltzman and Stanley Goetsch as executive directors (effective 30 June 2026) confirmed; FY2027 outlook: 35 stores, total income margin 32.0% in the first 10 weeksLeadership transition
29 May 2026New R500m two-year bullet loan (extendable to three years) disclosedFunding of the growth programme
1 Jun 2026CEO media commentary: wholesale margin pressure (8.2% → 7.2%), dispensary margin pressure, Better Rewards sustainabilityInvestor focus on margin mix
22 Jun 2026Final FY2026 dividend paid—
30 Jun 2026Ivan Saltzman and Goetsch retire as executivesEnd of founder executive era
3 Jul 2026Integrated annual report: chairman cites persistent affordability pressure; Dis-Chem Health and Life growing; wholesale serves 1,600+ independent pharmaciesStrategy reaffirmed
17–20 Jul 2026Saul Saltzman resigns from the boardFamily exit
23 Jul 2026Ivan Saltzman resigns from the board; share price falls 4.1% on the day (to R29.85)Founder departure complete
31 Jul 2026AGM: operating model restructured to create clear accountability; investment in ecosystem reaffirmed—
Aug 2026Store of the Future design becomes mandatory for new stores (from 1 August)Execution milestone
28 Aug–14 Sep 2026Shares slide from R28.80 to R25.78; 52-week change about −15%Market scepticism on the payback of the ecosystem
30 Oct 2026 (scheduled)H1 FY2027 interim results dueNext major catalyst (FY2027 earnings recovery test)

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from ZAR 30,407 Mn in FY2022 to ZAR 42,826 Mn in FY2026.
Dis-Chem Pharmacies Limited — Income Statement: Revenue & Gross Profit
Series (ZAR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue30,40732,66436,28339,17242,826
Cost of sales23,57625,07628,06730,37233,417
Gross profit6,8307,5878,2178,8009,409
Finance costs, gross325370466521554

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.